Lisata Therapeutics, Inc.

David J. Mazzo, Ph.D., President & CEO of Lisata, will be presenting at GCFF’s Virtual Bio Investing Conference at 10:00 a.m. PT on Thursday, June 20, 2024.

Register for the conference at: https://www.eventbrite.ca/e/gcff-virtual-2024-bio-investing-conference-tickets-905051061087

Lisata Therapeutics Announces Full Enrollment of Pancreatic Cancer Cohort of CENDIFOX Trial

Read full release for more details: https://ir.lisata.com/news-releases/news-release-details/lisata-therapeutics-announces-full-enrollment-pancreatic-cancer

At Lisata Therapeutics, we are dedicated to developing groundbreaking treatments for difficult-to-treat solid tumors, including pancreatic cancer. Our lead asset, certepetide, has the potential to be a game changer in pancreatic cancer treatment and the treatment of other types of solid tumors as it’s designed to overcome the challenges of the tumor stroma and helps tame the tumor microenvironment, enhancing the efficacy of existing chemotherapies and other anti-cancer treatments.

Learn more from Proactive: https://www.proactiveinvestors.com/companies/news/1048581/how-does-lisata-therapeutics-have-a-negative-enterprise-value-1048581.html

How does Lisata Therapeutics have a negative enterprise value? Lisata Therapeutics Inc (NASDAQ:LSTA) finds itself in an extraordinary but not unusual position emblematic of the challenges faced by small-cap biotech...

We are pleased to share that our President & CEO, Dr. David J. Mazzo, will be speaking at the BIO International Convention in San Diego!

Dr. Mazzo will present on Monday, June 3 at 2:15 p.m. PT.

For updates and more information on the event, please visit https://convention.bio.org/about-bio?gad_source=1&gclid=EAIaIQobChMI3YWnsNTvhQMVATYIBR12XA0zEAAYASAAEgLFjfD_BwE

Lisata President & CEO, David J. Mazzo, Ph.D., will be speaking at the 10th Annual Oncology Innovation Forum on Friday, May 31, at 10:50 a.m. Central Time.

To learn more about the event, please visit: https://www.sachsforum.com/10oif-about.html

Lisata Therapeutics to Participate in Upcoming June 2024 Industry and Investor Events

We look forward to connecting with partners, leaders, and innovators next month!

Read full release for event details: https://ir.lisata.com/news-releases/news-release-details/lisata-therapeutics-participate-upcoming-june-2024-industry-and

Lisata President & CEO, David J. Mazzo, PhD, delivered a company presentation today, May 22, at the Pharma Partnering EU Summit in Basel, Switzerland.

This summit is a must-attend event bringing together senior executives from around the world. To learn more about the event, please visit: https://pharma-partnering-summit.com/eu-pps.html

Lisata Therapeutics Receives Paediatric Investigation Plan Waiver from the European Medicines Agency for Certepetide in Pancreatic Cancer

Read the full release at: https://ir.lisata.com/news-releases/news-release-details/lisata-therapeutics-receives-paediatric-investigation-plan

Lisata Therapeutics gets 2024 off to a strong start as it prepares for crucial ASCEND trial results Lisata Therapeutics Inc (NASDAQ:LSTA) CEO David Mazzo tells Proactive's Stephen Gunnion that 2024 is a pivotal year for the oncology company, with Phase 2b A...

Lisata reports its First Quarter 2024 Financial Results and Business Update.

Read full release: https://ir.lisata.com/news-releases/news-release-details/lisata-therapeutics-reports-first-quarter-2024-financial-results

Tune in to the webcast at 4:30 p.m. here: https://edge.media-server.com/mmc/p/7rojosoe/

Today, May 9, we will announce our First Quarter 2024 Financial Results after the close of trading and will host a conference call at 4:30 p.m. ET.

To participate on the call, please register here: https://register.vevent.com/register/BIe92b4878c5094e279c1fb7ee3d85e385

Tune in to the webcast here: https://edge.media-server.com/mmc/p/7rojosoe/

We’re excited to announce our participation in several key industry and investor events taking place this May! Don’t miss the chance to connect with us and learn more about our groundbreaking work in treating advanced solid tumors and other serious diseases.

Pharma Partnering U.S. Summit, May 14-15, 2024, in San Diego, California. Available for one-on-one meetings: Tariq Imam, VP of Business Development & Operations.

BioNJ Virtual BioPartnering Conference, May 15-17, 2024. Available for one-on-one meetings: Tariq Imam, VP of Business Development & Operations.

Pharma Partnering EU Summit, May 22-23, 2024, in Basel, Switzerland. David Mazzo, PhD, President & CEO will present a company overview on May 22 at 12:30 p.m. CEST.

10th Annual Oncology Innovation Forum, May 31, 2024, in Chicago, Illinois. David J. Mazzo, PhD, President & CEO, will present a company overview on: May 31 at 10:50 a.m. CT / 11:50 a.m. ET.

2024 ASCO Annual Meeting, May 31 - June 4, 2024, Chicago, Illinois. Management will be available for one-on-one meetings.

We’re looking forward to engaging with partners, industry leaders, and innovators. See you there!

Read our full event announcement for more details about each event: https://ir.lisata.com/news-releases/news-release-details/lisata-therapeutics-participate-upcoming-may-2024-industry-and

On Thursday, May 9, we will announce our First Quarter 2024 financial results after the close of trading and will host a conference call at 4:30 p.m. ET.

See here for the full announcement and details on how to participate in the call:

https://ir.lisata.com/news-releases/news-release-details/lisata-therapeutics-report-first-quarter-2024-financial-results

We were proud to once again take part in the Pancreatic Cancer Action Network PurpleStride Walk this past Saturday, April 27th. This event raises awareness and funds for the Pancreatic Cancer Action Network's vital work supporting patients, caregivers, and driving research for better pancreatic cancer treatments.

A huge thank you goes out to all our employees who participated, donated, and helped raise funds for this important cause. Together, we're getting one step closer to improving outcomes for pancreatic cancer patients and their loved ones.

Lisata Therapeutics advances lead asset LSTA1 for treatment of advanced solid tumors Lisata Therapeutics CEO David J. Mazzo discusses the oncology company's focus and recent advancements in an interview with Proactive's Stephen Gunnion. Lisat...

Press Release: https://loom.ly/KVzF4BM

Register for the Webinar: https://loom.ly/Wtz8oaE

Lisata Therapeutics Announces U.S. FDA Orphan Drug Designation Granted to LSTA1 for the Treatment of Osteosarcoma. View details: https://ir.lisata.com/news-releases/news-release-details/lisata-therapeutics-announces-us-fda-orphan-drug-designation-0

Lisata Therapeutics to Participate in Upcoming April 2024 Industry and Investor Events. View details: https://ir.lisata.com/news-releases/news-release-details/lisata-therapeutics-participate-upcoming-april-2024-industry-and

Lisata Therapeutics Announces U.S. FDA Rare Pediatric Disease Designation Granted to LSTA1 for the Treatment of Osteosarcoma.

View details: https://ir.lisata.com/news-releases/news-release-details/lisata-therapeutics-announces-us-fda-rare-pediatric-disease

If you’ve been diagnosed with or , a global multi-center clinical trial evaluating an investigational drug in combination with FDA approved standard-of-care may be an option for you. Learn more: https://bit.ly/bolster-trial

Lisata Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update. View details: https://ir.lisata.com/news-releases/news-release-details/lisata-therapeutics-reports-full-year-2023-financial-results-and

As a reminder, Lisata will host its Full Year 2023 Financial Results conference call today at 4:30 p.m. (ET). Please use the following link to register: https://register.vevent.com/register/BI41a2d73e585c4f67a2be8707fd9c352e

Make a difference through clinical trial participation!
See if you qualify for a clinical trial evaluating the impact of an investigational drug in people with and . Learn more: https://bit.ly/bolster-trial

Lisata Therapeutics to Host Year-End 2023 Conference Call on Thursday, February 29, 2024 at 4:30 p.m. Eastern Time. View details: https://ir.lisata.com/news-releases/news-release-details/lisata-therapeutics-host-year-end-2023-conference-call-thursday

Join Lisata's President and CEO, David Mazzo, for a company presentation at the BIO CEO & Investor Conference in NY. View details: https://ir.lisata.com/news-releases/news-release-details/lisata-therapeutics-present-bio-ceo-investor-conference

Are you living with (bile duct cancer) or head and neck cancer?

A clinical trial evaluating an investigational drug as a potential treatment for these solid tumor types is now recruiting patients. See if you qualify: https://bit.ly/bolster-trial

February is Cholangiocarcinoma Awareness Month. Lisata is joining hands with the Cholangiocarcinoma Foundation to spread awareness about cholangiocarcinoma ( ), a rare cancer of the bile duct. Together, we can support CCA community efforts in patient education, advocacy and research: https://cholangiocarcinoma.org

The BOLSTER trial is evaluating the safety and effectiveness of an investigational drug in combination with standard-of-care in advanced solid tumors including and . Learn more:

A Study of LSTA1 When Added to Standard of Care Versus Standard of Care Alone in Patients With Advanced Solid Tumors - Full Text View - ClinicalTrials.gov A Study of LSTA1 When Added to Standard of Care Versus Standard of Care Alone in Patients With Advanced Solid Tumors - Full Text View.